1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study

Collapse authors list.
Leavy, OC, Russell, RJ ORCID: 0000-0002-0195-0812, Harrison, EM, Lone, NI ORCID: 0000-0003-2707-2779, Kerr, S, Docherty, AB, Sheikh, A, Richardson, M, Elneima, O ORCID: 0000-0003-2480-8840, Greening, NJ ORCID: 0000-0003-0453-7529 et al (show 63 more authors) , Harris, VC, Houchen-Wolloff, L, McAuley, HJC ORCID: 0000-0001-8997-0764, Saunders, RM, Sereno, M, Shikotra, A, Singapuri, A, Aul, R, Beirne, P, Bolton, CE ORCID: 0000-0002-9578-2249, Brown, JS, Choudhury, G, Bakerly, ND, Easom, N, Echevarria, C, Fuld, J, Hart, N ORCID: 0000-0002-6863-585X, Hurst, JR ORCID: 0000-0002-7246-6040, Jones, M ORCID: 0000-0001-6308-6014, Parekh, D ORCID: 0000-0002-1508-8362, Pfeffer, P, Rahman, NM, Rowland-Jones, S, Shah, AM, Wootton, DG ORCID: 0000-0002-5903-3881, Jolley, C ORCID: 0000-0003-3538-2451, Roger Thompson, AA ORCID: 0000-0002-0717-4551, Chalder, T, Davies, MJ, De Soyza, A ORCID: 0000-0002-8566-0344, Geddes, JR, Greenhalf, W ORCID: 0000-0002-1865-3195, Heller, S, Howard, L ORCID: 0000-0003-2822-210X, Jacob, J ORCID: 0000-0002-8054-2293, Jenkins, RG, Lord, JM, Man, WDC ORCID: 0000-0002-3782-659X, McCann, GP, Neubauer, S, Openshaw, PJM ORCID: 0000-0002-7220-2555, Porter, J ORCID: 0000-0002-7307-169X, Rowland, MJ, Scott, JT, Semple, MG ORCID: 0000-0001-9700-0418, Singh, SJ ORCID: 0000-0002-9834-0366, Thomas, D, Toshner, M ORCID: 0000-0002-3969-6143, Lewis, K, Heaney, LG, Briggs, A, Zheng, B, Thorpe, M, Quint, JK ORCID: 0000-0003-0149-4869, Chalmers, JD, Ho, LP, Horsley, A ORCID: 0000-0003-1828-0058, Marks, M ORCID: 0000-0002-7585-4743, Poinasamy, K, Raman, B ORCID: 0000-0002-1239-9608, Wain, LV ORCID: 0000-0003-4951-1867, Brightling, CE and Evans, RA ORCID: 0000-0002-1667-868X (2024) 1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study Erj Open Research, 10 (5). pp. 474-2024. ISSN 2312-0541, 2312-0541

PDF 1-year health outcomes associated with systemic corticosteroids for COVID-19 a longitudinal cohort study.pdf - Open Access published version Download (1MB) | Preview

Abstract

Background In patients with coronavirus disease 2019 (COVID-19) requiring supplemental oxygen, dexamethasone reduces acute severity and improves survival, but longer-term effects are unknown. We hypothesised that systemic corticosteroid administration during acute COVID-19 would be associated with improved health-related quality of life (HRQoL) 1 year after discharge. Methods Adults admitted to hospital between February 2020 and March 2021 for COVID-19 and meeting current guideline recommendations for dexamethasone treatment were included using two prospective UK cohort studies (Post-hospitalisation COVID-19 and the International Severe Acute Respiratory and emerging Infection Consortium). HRQoL, assessed by the EuroQol-Five Dimensions–Five Levels utility index (EQ-5D-5L UI), pre-hospital and 1 year after discharge were compared between those receiving corticosteroids or not after propensity weighting for treatment. Secondary outcomes included patient-reported recovery, physical and mental health status, and measures of organ impairment. Sensitivity analyses were undertaken to account for survival and selection bias. Findings Of the 1888 participants included in the primary analysis, 1149 received corticosteroids. There was no between-group difference in EQ-5D-5L UI at 1 year (mean difference 0.004, 95% CI −0.026–0.034). A similar reduction in EQ-5D-5L UI was seen at 1 year between corticosteroid exposed and nonexposed groups (mean±SD change −0.12±0.22 versus −0.11±0.22). Overall, there were no differences in secondary outcome measures. After sensitivity analyses modelled using a cohort of 109 318 patients admitted to hospital with COVID-19, EQ-5D-5L UI at 1 year remained similar between the two groups. Interpretation Systemic corticosteroids for acute COVID-19 have no impact on the large reduction in HRQoL 1 year after hospital discharge. Treatments to address the persistent reduction in HRQoL are urgently needed.

Item Type:	Article
Uncontrolled Keywords:	32 Biomedical and Clinical Sciences, 3202 Clinical Sciences, Coronaviruses Disparities and At-Risk Populations, Infectious Diseases, Lung, Coronaviruses, Emerging Infectious Diseases, 6.1 Pharmaceuticals, 3 Good Health and Well Being
Divisions:	Faculty of Health & Life Sciences Faculty of Health & Life Sciences > Inst. Infection, Vet & Ecological Sciences
Depositing User:	Symplectic Admin
Date Deposited:	04 Nov 2024 11:30
Last Modified:	06 Feb 2026 19:05
DOI:	10.1183/23120541.00474-2024
Related Websites:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3187054
Disclaimer:	The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.